Literature DB >> 28485129

Evaluation of algorithms to identify incident cancer cases by using French health administrative databases.

Aya Ajrouche1,2,3, Candice Estellat1,2,3, Yann De Rycke1,2,3, Florence Tubach1,2,3,4.   

Abstract

PURPOSE: Administrative databases are increasingly being used in cancer observational studies. Identifying incident cancer in these databases is crucial. This study aimed to develop algorithms to estimate cancer incidence by using health administrative databases and to examine the accuracy of the algorithms in terms of national cancer incidence rates estimated from registries.
METHODS: We identified a cohort of 463 033 participants on 1 January 2012 in the Echantillon Généraliste des Bénéficiaires (EGB; a representative sample of the French healthcare insurance system). The EGB contains data on long-term chronic disease (LTD) status, reimbursed outpatient treatments and procedures, and hospitalizations (including discharge diagnoses, and costly medical procedures and drugs). After excluding cases of prevalent cancer, we applied 15 algorithms to estimate the cancer incidence rates separately for men and women in 2012 and compared them to the national cancer incidence rates estimated from French registries by indirect age and sex standardization.
RESULTS: The most accurate algorithm for men combined information from LTD status, outpatient anticancer drugs, radiotherapy sessions and primary or related discharge diagnosis of cancer, although it underestimated the cancer incidence (standardized incidence ratio (SIR) 0.85 [0.80-0.90]). For women, the best algorithm used the same definition of the algorithm for men but restricted hospital discharge to only primary or related diagnosis with an additional inpatient procedure or drug reimbursement related to cancer and gave comparable estimates to those from registries (SIR 1.00 [0.94-1.06]).
CONCLUSION: The algorithms proposed could be used for cancer incidence monitoring and for future etiological cancer studies involving French healthcare databases.
Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  algorithms; cancer; health insurance data; incidence; pharmacoepidemiology

Mesh:

Year:  2017        PMID: 28485129     DOI: 10.1002/pds.4225

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS).

Authors:  Elise Dumas; Lucie Laot; Florence Coussy; Beatriz Grandal Rejo; Eric Daoud; Enora Laas; Amyn Kassara; Alena Majdling; Rayan Kabirian; Floriane Jochum; Paul Gougis; Sophie Michel; Sophie Houzard; Christine Le Bihan-Benjamin; Philippe-Jean Bousquet; Judicaël Hotton; Chloé-Agathe Azencott; Fabien Reyal; Anne-Sophie Hamy
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

2.  Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.

Authors:  Xavier Mariette; Florence Tubach; Raphaele Seror; Alexandre Lafourcade; Yann De Rycke; Sandrine Pinto; Johann Castaneda; Bruno Fautrel
Journal:  RMD Open       Date:  2022-06

3.  Cancer care and public health policy evaluations in France: Usefulness of the national cancer cohort.

Authors:  Philippe Jean Bousquet; Delphine Lefeuvre; Philippe Tuppin; Marc Karim BenDiane; Mathieu Rocchi; Elsa Bouée-Benhamiche; Jérôme Viguier; Christine Le Bihan-Benjamin
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

4.  Validation of Cancer Diagnosis Based on the National Health Insurance Service Database versus the National Cancer Registry Database in Korea.

Authors:  Min Soo Yang; Minae Park; Joung Hwan Back; Gyeong Hyeon Lee; Ji Hye Shin; Kyuwoong Kim; Hwa Jeong Seo; Young Ae Kim
Journal:  Cancer Res Treat       Date:  2021-08-02       Impact factor: 5.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.